Public Meetings and Conferences
U.S. Department of Defense’s Joint Project Manager for Medical Countermeasure Systems (JPM-MCS) Industry Day: Proposed Other Transaction Agreement (OTA)
Register for this free event at: https://www.surveyshield.com/TakeSurvey.asp?SurveyID=40H8o3009om1K2
The U.S. Department of Defense’s Joint Project Manager for Medical Countermeasure Systems (JPM-MCS) will host a second Industry Day on a proposed Other Transaction Agreement from 8am to 5pm on Monday, November 2 at the Crowne Plaza Fairfield, 690 Route 46 East, Fairfield, NJ. You can register for this free event at: https://www.surveyshield.com/TakeSurvey.asp?SurveyID=40H8o3009om1K2. The last day to register is Monday, November 2.
JPM-MCS provided information during a first industry day informing potential offerors of expected research and development tasks under an “Other Transaction Agreement”. An entity or group of entities eligible for award include industry, academic, non-profit, and not-for-profit partners, for advanced development efforts supporting the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements enhancing the mission effectiveness of military personnel.
Please note JPM-MCS will use this second industry day to provide information on the objectives and requirements of the consortium OTA, and provide any updates based on the information received from attendees at the industry day held in conjunction with BIO 2015 in Philadelphia on 15 June. At this second industry day, JPM-MCS will request Letters of Intent from those who might form a consortium to determine if and how to move forward. Our expectation is that a successful consortium will include members with a history of successful experience in regulatory review.
Who we are
JPM-MCS is a U.S. Department of Defense program within the Joint Program Executive Office for Chemical and Biological Defense. JPM-MCS provides U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear (CBRN) threats. We contract to develop products in three major areas:
Diagnostics: Systems and devices to identify CBRN agents and assist in making medical decisions
Prevention: Prophylaxis, pretreatment, post-exposure prophylaxis
Treatment: Therapeutics (post-exposure, post-symptomatic)
If you have questions about this contracting opportunity after reading the notice, email them to Kristen Kachur at email@example.com. For more information about Industry Day, email Clay Holloway at firstname.lastname@example.org.